Decreased Immunologic Activity

Accession Number

DBCAT004157

Description

Not Available

Drugs

Drug	Drug Description
Muromonab	A monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
Everolimus	A mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies.
Sirolimus	An mTOR inhibitor immunosuppressant used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors.

Drugs & Drug Targets

Drug	Target	Type
Muromonab	T-cell surface glycoprotein CD3 epsilon chain	target
Muromonab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Muromonab	T-cell surface glycoprotein CD3 delta chain	target
Muromonab	T-cell surface glycoprotein CD3 gamma chain	target
Muromonab	T-cell surface glycoprotein CD3 zeta chain	target
Everolimus	Serine/threonine-protein kinase mTOR	target
Everolimus	Cytochrome P450 3A4	enzyme
Everolimus	Solute carrier organic anion transporter family member 1B1	transporter
Everolimus	Solute carrier organic anion transporter family member 1B3	transporter
Everolimus	Solute carrier organic anion transporter family member 1A2	transporter
Everolimus	Cytochrome P450 2D6	enzyme
Everolimus	P-glycoprotein 1	transporter
Sirolimus	Cytochrome P450 3A4	enzyme
Sirolimus	Serine/threonine-protein kinase mTOR	target
Sirolimus	Cytochrome P450 3A5	enzyme
Sirolimus	Cytochrome P450 3A7	enzyme
Sirolimus	P-glycoprotein 1	transporter
Sirolimus	Solute carrier organic anion transporter family member 1B1	transporter
Sirolimus	Multidrug and toxin extrusion protein 1	transporter
Sirolimus	Serum albumin	carrier
Sirolimus	Alpha-1-acid glycoprotein 1	carrier
Sirolimus	Apolipoproteins	carrier